PharmaCyte Biotech, Inc.
PMCB
$0.55
$0.000.73%
NASDAQ
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -19.42M | -3.28M | -7.07M | -1.13M | 30.66M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16.20M | -1.93M | 1.70M | -3.75M | -34.99M |
| Change in Net Operating Assets | -1.93M | 411.90K | 854.90K | 275.90K | 1.36M |
| Cash from Operations | -5.15M | -4.80M | -4.52M | -4.60M | -2.98M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.00M | 2.00M | -3.00M | 0.00 | -7.00M |
| Cash from Investing | 2.00M | 2.00M | -3.00M | 0.00 | -7.00M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.05M | 1.05M | -- | -- | -- |
| Repurchase of Common Stock | -401.60K | -573.10K | -396.50K | -1.80M | -2.54M |
| Issuance of Preferred Stock | 6.27M | 6.27M | 6.27M | -- | -- |
| Repurchase of Preferred Stock | -86.40K | 0.00 | -3.72M | -13.06M | -22.49M |
| Total Dividends Paid | -246.10K | -162.70K | -61.30K | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6.58M | 6.58M | 2.09M | -14.86M | -25.03M |
| Foreign Exchange rate Adjustments | 3.00K | 2.90K | -900.00 | -400.00 | -300.00 |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3.43M | 3.78M | -5.43M | -19.46M | -35.01M |